HCA Healthcare, one of the largest hospital systems in the United States, recently made the decision to stop covering popular obesity drugs Zepbound and Wegovy for its employees starting next year. Instead, the company directed its employees to explore alternative options to obtain these medications, such as enrolling in discount programs offered by the drugs’ manufacturers, Eli Lilly and Novo Nordisk.
According to a notice obtained by STAT, HCA noted a significant 90% increase in the use of GLP-1 weight loss drugs this year, leading to a substantial rise in costs. By steering employees towards the manufacturers’ discount programs, HCA aims to reduce its expenses associated with providing these medications through insurance coverage.
Craig Garthwaite, director of health care at Northwestern University’s Kellogg School of Management, highlighted the cost-saving benefits for companies like HCA in utilizing manufacturer discount programs. He explained that by directing employees to purchase the drugs through these programs, employers can potentially secure lower prices compared to what they would pay through traditional insurance coverage.
This trend of cutting coverage for weight loss drugs is not unique to HCA, as other companies are also considering similar actions to control costs. The increasing availability of discount programs from pharmaceutical companies like Eli Lilly and Novo Nordisk may be influencing this shift in coverage decisions. These programs, which offer medications at discounted cash prices, are being promoted as a way to improve access to treatment options.
The complexity of the U.S. healthcare system, which involves various entities like pharmacy benefits managers and manufacturer rebates, often obscures the actual costs of medications for employers. Jim Winkler, chief strategy officer of the Business Group on Health, noted that some companies are now questioning whether they are overpaying for obesity drugs compared to the discounted cash prices offered through manufacturer programs. This realization has led companies to consider the option of employees purchasing these medications independently.
In the case of HCA, the company acknowledged in its notice that the discounts available through Lilly and Novo’s programs may make the medications more affordable for employees than the negotiated prices through group health plans. This shift in coverage strategy reflects a growing trend among employers to reassess the value of traditional insurance coverage for certain medications.
Overall, the decision by HCA and other companies to discontinue coverage for obesity drugs in favor of manufacturer discount programs underscores the evolving landscape of healthcare cost management. As employers navigate the complexities of providing healthcare benefits to their employees, they are increasingly exploring alternative approaches to ensure cost-effective access to essential medications.
